155 related articles for article (PubMed ID: 30131167)
1. Effectiveness of the «cognitive» biopsy in the diagnosis of prostate cancer in patients with a previous negative biopsy.
Barbas Bernardos G; Herranz Amo F; de Miguel Campos E; Luis Cardo A; Herranz Arriero A; Caño Velasco J; Cancho Gil MJ; Jara Rascón J; Mayor de Castro J; Hernández Fernández C
Actas Urol Esp (Engl Ed); 2019; 43(1):12-17. PubMed ID: 30131167
[TBL] [Abstract][Full Text] [Related]
2. Comparison of classical transrectal prostate biopsy versus cognitive registration in rebiopsy.
Barbas Bernardos G; Herranz Amo F; de Miguel Campos E; Luis Cardo A; Herranz Arriero A; Cancho Gil MJ; Caño Velasco J; Jara Rascón J; Mayor de Castro J; Hernández Fernández C
Actas Urol Esp (Engl Ed); 2019 Jun; 43(5):228-233. PubMed ID: 30833102
[TBL] [Abstract][Full Text] [Related]
3. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
4. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
[TBL] [Abstract][Full Text] [Related]
5. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
6. Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1.
Apfelbeck M; Pfitzinger P; Bischoff R; Rath L; Buchner A; Mumm JN; Schlenker B; Stief CG; Chaloupka M; Clevert DA
Clin Hemorheol Microcirc; 2020; 76(4):503-511. PubMed ID: 33337358
[TBL] [Abstract][Full Text] [Related]
7. Prostate imaging-reporting and data system version 2 in combination with clinical parameters for prostate cancer detection: a single center experience.
Wang L; Luo Y; Liu T; Deng M; Huang X
Int Urol Nephrol; 2023 Jul; 55(7):1659-1664. PubMed ID: 37171702
[TBL] [Abstract][Full Text] [Related]
8. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
[TBL] [Abstract][Full Text] [Related]
9. Systematic and MRI-Cognitive Targeted Transperineal Prostate Biopsy Accuracy in Detecting Clinically Significant Prostate Cancer after Previous Negative Biopsy and Persisting Suspicion of Malignancy.
Vėželis A; Platkevičius G; Kinčius M; Gumbys L; Naruševičiūtė I; Briedienė R; Petroška D; Ulys A; Jankevičius F
Medicina (Kaunas); 2021 Jan; 57(1):. PubMed ID: 33435132
[No Abstract] [Full Text] [Related]
10. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
11. Central zone lesions on magnetic resonance imaging: Should we be concerned?
Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer.
Kaufmann S; Bedke J; Gatidis S; Hennenlotter J; Kramer U; Notohamiprodjo M; Nikolaou K; Stenzl A; Kruck S
World J Urol; 2016 Apr; 34(4):509-15. PubMed ID: 26267808
[TBL] [Abstract][Full Text] [Related]
13. Improving the understanding of PI-RADS in practice: characters of PI-RADS 4 and 5 lesions with negative biopsy.
Wang YH; Liang C; Zhu FP; Zhou TR; Li J; Wang ZJ; Liu BJ
Asian J Androl; 2023; 25(2):217-222. PubMed ID: 36722578
[TBL] [Abstract][Full Text] [Related]
14. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
[TBL] [Abstract][Full Text] [Related]
15. Do patients with a PI-RADS 5 lesion identified on magnetic resonance imaging require systematic biopsy in addition to targeted biopsy?
Drobish JN; Bevill MD; Tracy CR; Sexton SM; Rajput M; Metz CM; Gellhaus PT
Urol Oncol; 2021 Apr; 39(4):235.e1-235.e4. PubMed ID: 33451935
[TBL] [Abstract][Full Text] [Related]
16. The Negative Predictive Value of a PI-RADS Version 2 Score of 1 on Prostate MRI and the Factors Associated With a False-Negative MRI Study.
Ma HY; Ahmed FS; Luk L; Martina LAP; Wenske S; Shaish H
AJR Am J Roentgenol; 2020 Sep; 215(3):667-672. PubMed ID: 32755155
[No Abstract] [Full Text] [Related]
17. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
18. In-bore MR prostate biopsy - initial experience.
Rembak-Szynkiewicz J; Wojcieszek P; Hebda A; Mazgaj P; Badziński A; Stasik-Pres G; Chmielik E; Bobek-Billewicz B
Endokrynol Pol; 2022; 73(4):712-724. PubMed ID: 35971938
[TBL] [Abstract][Full Text] [Related]
19. Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
Viana PCC; Horvat N; do Santos VR; Lima TC; Romão DDS; Cerri LMO; de Castro MG; Vargas HA; Miranda JA; Leite CDC; Cerri GG
Int Braz J Urol; 2019; 45(4):724-731. PubMed ID: 31136114
[TBL] [Abstract][Full Text] [Related]
20. PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists.
Bhayana R; O'Shea A; Anderson MA; Bradley WR; Gottumukkala RV; Mojtahed A; Pierce TT; Harisinghani M
AJR Am J Roentgenol; 2021 Jul; 217(1):141-151. PubMed ID: 32903060
[No Abstract] [Full Text] [Related]
[Next] [New Search]
